Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …

Regulatory T cells (Tregs) characterized by the expression of the master transcription factor
forkhead box protein p3 (Foxp3) suppress anticancer immunity, thereby hindering protective …

With the broad application of cancer immunotherapies such as immune checkpoint inhibitors
in multiple cancer types, the immunological landscape in the tumor microenvironment (TME) …

Naturally occurring CD4+ regulatory T cells (Tregs), which specifically express the
transcription factor FoxP3 in the nucleus and CD25 and CTLA-4 on the cell surface, are a …

The success of immunotherapy in oncology underscores the vital role of the immune system
in cancer development. Regulatory T cells (Tregs) maintain a fine balance between …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

The capacity of targeted anticancer agents to exert immunomodulatory effects provides a
strong rationale to develop novel agents suitable for combinatorial regimens with …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Gastric cancer (GC) is a highly aggressive malignancy that remains a significant contributor
to cancer-related mortality worldwide, despite a decline in incidence in recent years. Early …